Celldex Therapeutics, Inc. announced positive results from a Phase 1 multi-dose study of CDX-301 demonstrating that CDX-301 was well-tolerated and can safely and effectively mobilize hematopoietic cell populations in healthy volunteers.
http://www.freshnews.com/news/737485/celldex-therapeutics-cdx-301-safely-mobilizes-hematopoietic-cells-phase-1-study-future-
http://www.freshnews.com/news/737485/celldex-therapeutics-cdx-301-safely-mobilizes-hematopoietic-cells-phase-1-study-future-
No comments:
Post a Comment